Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

International Immunopharmacology

Volumn 8, Issue 10, 2008, Pages 1401-1407

  Cho, Hyeon Cheol ^a   Kim, Bo Hwan ^a   Kim, Kyunghoon ^b   Park, Ju Youn ^a   Chang, Jae Ho ^a   Kim, Soo Ki ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Cancer; CpG ODN; Cytokine; Immunotherapy; NK cell

Indexed keywords

CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; IN VITRO SELECTION; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ANIMALS; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50949102674     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.05.010     Document Type: Article

References (22)

1. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 (2001) 675-680
2. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1) immunity. J Exp Med 186 (1997) 1623-1631
3. Duin D.R., Medzhitov, and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 (2006) 49-55
4. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci U S A 93 (1996) 2879-2883
5. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
6. Krieg A.M., Yi A.K., Matson S., Waldscjmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 374 (1995) 546-549
7. Krug A., Rothenfusser S., Hornung V., Jahrsdörfer B., Blackewll S., Ballas Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 31 (2001) 2154-2163
8. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int Immunol 17 (2005) 1-14
9. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Wldschmidt M., et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167 (2001) 4878-4886
10. Carpentier A., Laigle-Donadey F., Zohar S., Capelle L., Behin A., Tibi A., et al. Phase 1 trial of a CpG oligonucleotide for patients with recurrent glioblastoma. Neuro-oncology 8 (2006) 60-66
11. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 105 (2005) 489-495
12. Gerda Goess M.P., Wagner C., Hormann M., Jandl T., Moser A., Britten C.M., et al. Phase II trial of a Toll-Like Recetor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24 (2006) 5716-5724
13. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 117 (2007) 1184-1194
14. Park S.J., Cho H.C., Bae K.S., and Kim S.K. Immunoadjuvanticity of novel CpG ODN (oligodeoxynucleotide). Mol Cell Toxicol 3 (2007) 46-52
15. Lee S.M., Kim K., Kim Y., Kim H.W., Shim B.I., Lee S.H., et al. The anti-inflammatory effect of IH-901 in HT-29 cells. Mol Cell Toxicol 3 (2007) 254-261
16. D'Agostini C., Pica F., Febbraro G., Grelli S., Chiavaroli C., and Garaci E. Antitumor effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 5 (2005) 1205-1212
17. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. Current protocols in immunology (2000), Wiely-interscience, New York 3.1.1-3.1.5
18. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., et al. Peritumoral CpG DNA elicits a coordinated response of CD8T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 168 (2002) 3892-3899
19. Roda J.M., Parihar R., and Carson III W.E. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175 (2005) 1619-1627
20. Switaj T., Jalili A., Jakubowska A.B., Drela N., Stoksik M., Nowis D., et al. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10 (2004) 4165-4175
21. Weigel B.J., Rodeberg D.A., Krieg A.M., and Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9 (2003) 3105-3114
22. Carpentier A.F., Chen L., Maltonti F., and Delattre J. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59 (1999) 5429-5432